2017-2020年流感流行季节河北省甲型H1N1流感病毒耐药性及耐药基因分析  

Drug resistance of influenza A(H1N1)pdm09 virus in Hebei,2017-2020

作　　者：姜彩肖[1] 韩光跃[1] 李岩[1] 刘艳芳[1] 刘兰芬[1] 齐顺祥[1] Jiang Caixiao;Han Guangyue;Li Yan;Liu Yanfang;Liu Lanfen;Qi Shunxiang(Institute for Viral Disease Prevention and Treatment,Hebei Provincial Center for Disease Control and Prevention,Shijiazhuang 050021,Hebei,China)

机构地区：[1]河北省疾病预防控制中心病毒性疾病防治所,河北石家庄050021

出　　处：《疾病监测》2021年第10期1081-1085,共5页Disease Surveillance

基　　金：河北省医学科学研究课题计划(No.20190142)。

摘　　要：目的分析河北省2017—2020年流感流行季节甲型H1N1流感病毒对神经氨酸酶抑制剂类药物(NAI)的耐药情况,为流感的预防控制提供依据。方法选取2017—2020年流感流行季节37株甲型H1N1流感病毒毒株进行生物学耐药实验,使用荧光发光法检测病毒对奥司他韦和扎那米韦的药物敏感性。选取38株甲型H1N1流感病毒提取核酸后对神经氨酸酶NA基因进行PCR扩增,测序后对耐药位点进行分析。结果选取的“A/河北新华/SWL1106/2017”对奥司他韦敏感性降低(IC50=30.98 nmol/L),其余36株甲型H1N1流感病毒全部对奥司他韦和扎那米韦敏感,对奥司他韦的半数抑制浓度(IC50)平均数为0.46(0.07~1.14)nmol/L;对扎那米韦的IC50平均数为0.27(0.07~0.85)nmol/L。序列分析发现1株发生了H275Y突变,为奥司他韦耐药株。结论2017—2020年河北省流行的绝大部分甲型H1N1流感病毒对NAI类药物敏感。Objective To analyze the resistance of influenza A(H1N1)pdm09 virus to neuraminidase inhibitors(NAIs)in Hebei province during 2017–2020 and provide evidence for the prevention and control of influenza.Methods A total of 37 strains of influenza A(H1N1)pdm09 virus isolated in Hebei during 2017–2020 were selected for oseltamivir and zanamivi resistance tests with fluorescence radiation assay.A total of 38 strains of influenza A(H1N1)pdm09 virus were selected for neuraminidase(NA)sequencing analysis.Results The median of half maximal inhibitory concentration(IC50)of oseltamivir to strain A/Hebeixinhua/SWL1106/2017 was 30.98 nmol/L.To 36 virus strains,the average IC50 of oseltamivir was of 0.46 nmol/L(ranged 0.07–1.14 nmol/L)while the average IC50 of zanamivi was 0.27 nmol/L(ranged 0.07–0.85 nmol/L).Sequence analysis showed that 1 strain had H275Y mutation in amino acid of the NA gene,suggesting that the strain was oseltamivir resistant.Conclusion The majority of influenza A(H1N1)pdm09 virus strains isolated in Hebei during 2017–2020 were sensitive to NAIs.

关 键 词：甲型H1N1流感病毒 神经氨酸酶抑制剂 耐药性 

分 类 号：R211[医药卫生—中医学] R183.3